Efficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studies

BACKGROUND: Psoriasis is characterized by a high frequency of comorbid metabolic disorders, including obesity and type 2 diabetes mellitus. There are limited data on the efficacy of glucagon-like peptide-1 receptor agonist for the treatment of metabolic disorders in patients with psoriasis.

AIM: Analysis of the effectiveness of liraglutide in the complex therapy of patients with psoriasis in combination with metabolic disorders.

MATERIALS AND METHODS: The PubMed database was searched for studies using the keywords "psoriasis" and "liraglutide". 23 publications were found, the final analysis included 5 studies with a total sample size of 52 patients with psoriasis combined with metabolic disorders (type 2 diabetes mellitus and obesity). The effect of liraglutide on the prevalence and severity of psoriasis was assessed by the dynamics of the lesion area and psoriasis severity index (PASI), quality of life according to the DLQI questionnaire and the level of fasting plasma glucose, glycated hemoglobin, and body mass index. The results are presented as the weighted mean difference (WMD) and 95% confidence interval (CI).

RESULTS: The duration of liraglutide therapy ranged from 8 to 16 weeks. The liraglutide dose was titrated from 0.6 mg/day to 3.0 mg/day. Significant dynamics of the WMD indices PASI (-6.95 [95% CI -11.59; -2.32]) and DLQI (-6.95 [95% CI -11.59; -2.32]), as well as the body mass index (-2.97 [95% CI -3.58; -2.37]) were demonstrated during liraglutide therapy. No significant difference in glucose and glycated hemoglobin levels was found.

CONCLUSION: The results of the meta-analysis demonstrate that the use of liraglutide in combination therapy for psoriasis helps to reduce BMI, the prevalence and severity of psoriasis, and improve the quality of life of patients.

1. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi: https://doi.org/10.1038/nutd.2012.26

2. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835. doi: https://doi.org/10.1016/j.jaad.2006.08.040

3. Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484-2490. doi: https://doi.org/10.1016/j.jid.2017.07.822

4. Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther. 2020;7(2):271-285. doi: https://doi.org/10.1007/s40744-020-00206-7

5. Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol. 2017;44(3):286-291. doi: https://doi.org/10.3899/jrheum.160861

6. Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010;59(2):143-145. doi: https://doi.org/10.1016/j.jdermsci.2010.06.004

7. Xue K, Liu H, Jian Q, et al. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro--a possible reason for increased severity of psoriasis in patients with a high body mass index. Exp Dermatol. 2013;22(6):406-410. doi: https://doi.org/10.1111/exd.12162

8. Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with comorbid psoriasis and obesity?. Expert Opin Pharmacother. 2019;20(11):1303-1308. doi: https://doi.org/10.1080/14656566.2019.1603294

9. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168(5):1124-1127. doi: https://doi.org/10.1111/bjd.12235

10. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863-872. doi: https://doi.org/10.1080/14656566.2019.1583207

11. Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73(6):1157-1162. doi: https://doi.org/10.1136/annrheumdis-2012-202812

12. Klingberg E, Björkman S, Eliasson B, Larsson I, Bilberg A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254. doi: https://doi.org/10.1186/s13075-020-02350-5

13. Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017;25(12):2068-2073. doi: https://doi.org/10.1002/oby.21955

14. Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery [published correction appears in JAMA Surg. 2018;153(7):692]. JAMA Surg. 2017;152(4):344-349. doi: https://doi.org/10.1001/jamasurg.2016.4610

15. Nasonov EL, Panevin TS, Troshina EA. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(2):135–144 (In Russ.) doi: https://doi.org/10.47360/1995-4484-2024-135-144

16. Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299-1305. doi: https://doi.org/10.1080/09546634.2021.1882658

17. Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: https://doi.org/10.1111/j.1468-3083.2012.04609.x

18. Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: https://doi.org/10.1111/bjd.12886

19. Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555-559. doi: https://doi.org/10.1111/jdv.12629

20. Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019;150:167-173. doi: https://doi.org/10.1016/j.diabres.2019.03.002

21. Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161(7):293-296. doi: https://doi.org/10.1016/j.medcli.2023.05.021

22. Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: https://doi.org/10.3389/fimmu.2023.1148209

23. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512. doi: https://doi.org/10.1124/pr.108.000604

24. Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150-152. doi: https://doi.org/10.1111/exd.12081

25. Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case. doi: https://doi.org/10.1530/EDM-21-0007

26. Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: https://doi.org/10.1530/EDM-23-0017